Research programme: siRNA therapeutics - siRNAsense

Drug Profile

Research programme: siRNA therapeutics - siRNAsense

Alternative Names: siRNA targeting tissue factor

Latest Information Update: 27 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator siRNAsense
  • Developer Polyplus-transfection; siRNAsense
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Cancer metastases; Prostate cancer

Highest Development Phases

  • Discontinued Cancer; Malignant melanoma; Neurological disorders; Prostate cancer

Most Recent Events

  • 27 Oct 2016 Discontinued - Preclinical for Cancer, Malignant melanoma, Neurological disorders and Prostate cancer in Norway as information for the products is unavailable on the company pipeline (siRNAsense pipeline, October 2016)
  • 09 Oct 2013 No development reported - Preclinical for Cancer in Norway (unspecified route)
  • 09 Oct 2013 No development reported - Preclinical for Malignant melanoma in Norway (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top